These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30056574)

  • 41. High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.
    Tyagi RK; Gleeson PJ; Arnold L; Tahar R; Prieur E; Decosterd L; Pérignon JL; Olliaro P; Druilhe P
    BMC Med; 2018 Oct; 16(1):181. PubMed ID: 30269689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    McLaurin EY; Holliday SL; Williams P; Brey RL
    Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery.
    Seavey MM; Lu LD; Stump KL
    Curr Protoc Pharmacol; 2011 Jun; Chapter 5():Unit 5.60. PubMed ID: 21935901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New therapeutics in systemic lupus erythematosus.
    Paz Z; Tsokos GC
    Curr Opin Rheumatol; 2013 May; 25(3):297-303. PubMed ID: 23492737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenetics of cutaneous lupus erythematosus.
    Hersh AO; Arkin LM; Prahalad S
    Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
    Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus.
    Luo S; Long H; Lu Q
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107028. PubMed ID: 33039962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment options for juvenile-onset systemic lupus erythematosus.
    Carreño L; López-Longo FJ; González CM; Monteagudo I
    Paediatr Drugs; 2002; 4(4):241-56. PubMed ID: 11960513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azathioprine therapy for patients with systemic lupus erythematosus.
    Abu-Shakra M; Shoenfeld Y
    Lupus; 2001; 10(3):152-3. PubMed ID: 11315344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus.
    Huang B; Jiang J; Luo B; Zhu W; Liu Y; Wang Z; Zhang Z
    J Cell Mol Med; 2018 Jul; 22(7):3330-3339. PubMed ID: 29570934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
    Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C
    Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
    Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
    Front Immunol; 2019; 10():2512. PubMed ID: 31708928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Progress and perspectives in the treatment of systemic lupus erythematosus].
    Robak E; Sysa-Jedrzejowska A; Wozniacka A
    Przegl Lek; 2005; 62(9):894-9. PubMed ID: 16541725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.
    Liu Y; Ye J; Shin Ogawa L; Inoue T; Huang Q; Chu J; Bates RC; Ying W; Sonderfan AJ; Rao PE; Zhou D
    PLoS One; 2015; 10(5):e0127361. PubMed ID: 25974040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secondary angle-closure glaucoma as an ocular presentation of systemic lupus erythematosus: a case report.
    Hou X; Pan W; Wang A; Yu T; Song A
    J Int Med Res; 2020 Sep; 48(9):300060520959492. PubMed ID: 32996806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-DNA autoantibodies and systemic lupus erythematosus.
    Blatt NB; Glick GD
    Pharmacol Ther; 1999 Aug; 83(2):125-39. PubMed ID: 10511458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis.
    Shamliyan TA; Dospinescu P
    Clin Ther; 2017 Jul; 39(7):1479-1506.e45. PubMed ID: 28673504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.